---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-22-000083"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2022-08-05T23:59:59+00:00"
generated_at: "2026-06-24T03:25:18.153198+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immunovant Q1 net loss $40.4M; initiates pivotal MG trial, TED trials on track

## Summary
- Net loss of $40.4M ($0.35/share) vs $30.5M ($0.31) YoY; R&D expenses up to $28.4M from $18.7M.
- Cash $427M as of June 30; expects runway into calendar 2025 despite $31M in CMC/clinical payments in Q1.
- Pivotal batoclimab trial in Myasthenia Gravis initiated June 2022; top-line data expected H2 2024.
- FDA alignment on two pivotal trials in Thyroid Eye Disease; trials to start H2 2022, data H1 2025.
- Investor call Sep 7 to announce two new batoclimab indications and third pivotal trial for 2022.

## SEC filing metadata
- accession: 0001764013-22-000083
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2022-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000083/0001764013-22-000083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000083/imvt-20220805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-22-000083
- JSON: https://secwatch.observer/filing/0001764013-22-000083.json
- Plain text: https://secwatch.observer/filing/0001764013-22-000083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.